Company helped healthcare professionals evaluate over 15,000 patients and wins industrywide acclaim in 2024
, /PRNewswire/ — Cytovale®, a commercial-stage medical diagnostics company, today celebrated a monumental year that catapulted it to lead the emerging sepsis diagnostics market, driven by increased demand for IntelliSep®, the company’s U.S. Food and Drug Administration (FDA)-cleared rapid sepsis detection solution. In the first full year of commercialization, Cytovale grew its customer base across three states and two health systems, demonstrated clinical improvements and financial savings for hospitals, and gained widespread industry recognition. This culminated in the company raising $100 million in Series D capital to further accelerate U.S. commercial expansion of IntelliSep in 2025.
AI-enabled IntelliSep uses sophisticated high-speed cameras and microfluidics to analyze the reaction of white blood cells from a patient showing signs and symptoms of sepsis. Using a standard blood draw, IntelliSep risk-stratifies patients based on their probability of having sepsis and …